We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
Posted: 28 May 2021Closes: 24 Nov 2021 08:31
Posted: 11 May 2021Closes: 07 Nov 2021 12:41
Posted: 09 May 2021Closes: 05 Nov 2021 14:11
Posted: 08 Mar 2021Closes: 04 Sep 2021 14:53
89Bio- Head/Senior Director of Regulatory Affairs
Posted: 01 Feb 2021Closes: 31 Jul 2021 10:27